Acorda Therapeutics Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 277

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 28

  • Investments
  • 7

Acorda Therapeutics General Information

Description

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. The company's Net product revenue is derived from the sales of Ampyra and Inbrija.

Contact Information

Website
www.acorda.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 2 Blue Hill Plaza
  • 3rd Floor, Pearl River
  • Ardsley, NY 10965
  • United States
Primary Industry
Pharmaceuticals
Acquirer
Merz Therapeutics (Germany)
Former Stock Listing
CDG
Corporate Office
  • 2 Blue Hill Plaza
  • 3rd Floor, Pearl River
  • Ardsley, NY 10965
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Acorda Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Acorda Therapeutics‘s full profile, request access.

Request a free trial

Acorda Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve
Pharmaceuticals
Ardsley, NY
277 As of 2024

Vienna, Austria
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Acorda Therapeutics Competitors (47)

One of Acorda Therapeutics’s 47 competitors is Pfizer (Vienna), a Corporation company based in Vienna, Austria.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pfizer (Vienna) Corporation Vienna, Austria
Evonile Pharma Private Equity-Backed Mumbai, India
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY
Pfizer Pakistan Corporation Karachi, Pakistan
IPI Legacy Liquidation Formerly VC-backed Seattle, WA
You’re viewing 5 of 47 competitors. Get the full list »

Acorda Therapeutics Patents

Acorda Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020223299-A1 Methods and compositions for treating cns injury Inactive 30-Apr-2019
CA-3059180-A1 Sustained release compositions of 4-aminopyridine Active 06-Apr-2017
CA-3059180-C Sustained release compositions of 4-aminopyridine Active 06-Apr-2017
CA-2999990-A1 Sustained release compositions of 4-aminopyridine Pending 29-Sep-2015
US-20180344649-A1 Sustained release compositions of 4-aminopyridine Inactive 29-Sep-2015 A61K9/2866
To view Acorda Therapeutics’s complete patent history, request access »

Acorda Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Acorda Therapeutics Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Acorda Therapeutics‘s full profile, request access.

Request a free trial

Acorda Therapeutics Investments & Acquisitions (7)

Acorda Therapeutics’s most recent deal was a Merger/Acquisition with Biotie Therapies for . The deal was made on 18-Apr-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Biotie Therapies 18-Apr-2016 Merger/Acquisition Drug Discovery
Civitas Therapeutics 23-Oct-2014 Merger/Acquisition Drug Delivery
NeurogesX 10-Jul-2013 Merger/Acquisition Pharmaceuticals
Qutenza 09-Jul-2013 Corporate Asset Purchase Buildings and Property
Neuronex 21-Dec-2012 Merger/Acquisition Pharmaceuticals
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Acorda Therapeutics Exits (1)

Acorda Therapeutics’s most recent exit was on 09-Jul-2013 from Qutenza. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Qutenza 09-Jul-2013 Completed
To view Acorda Therapeutics’s complete exits history, request access »

Acorda Therapeutics FAQs

  • When was Acorda Therapeutics founded?

    Acorda Therapeutics was founded in 1995.

  • Where is Acorda Therapeutics headquartered?

    Acorda Therapeutics is headquartered in Ardsley, NY.

  • What is the size of Acorda Therapeutics?

    Acorda Therapeutics has 277 total employees.

  • What industry is Acorda Therapeutics in?

    Acorda Therapeutics’s primary industry is Pharmaceuticals.

  • Is Acorda Therapeutics a private or public company?

    Acorda Therapeutics is a Private company.

  • What is the current valuation of Acorda Therapeutics?

    The current valuation of Acorda Therapeutics is .

  • What is Acorda Therapeutics’s current revenue?

    The current revenue for Acorda Therapeutics is .

  • How much funding has Acorda Therapeutics raised over time?

    Acorda Therapeutics has raised $753M.

  • Who are Acorda Therapeutics’s investors?

    BlackRock, Cross Atlantic Partners, EDBI, Easton Capital Investment Group, and Endpoint Late Stage Fund are 5 of 27 investors who have invested in Acorda Therapeutics.

  • Who are Acorda Therapeutics’s competitors?

    Pfizer (Vienna), Evonile Pharma, Regeneron Pharmaceuticals, Pfizer Pakistan, and IPI Legacy Liquidation are some of the 47 competitors of Acorda Therapeutics.

  • When was Acorda Therapeutics acquired?

    Acorda Therapeutics was acquired on 10-Jul-2024.

  • Who acquired Acorda Therapeutics?

    Acorda Therapeutics was acquired by Merz Therapeutics (Germany).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process